News
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over ... “They are being cut off cold-turkey, their prescription no longer fillable,” he said in a statement.
On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss ... agency's shortage list. Now that the FDA has decided tirzepatide is no longer ...
Eli Lilly’s (NYSE:LLY) popular weight loss ... drug Wegovy. However, according to updated federal data, three out of five dosing strengths of Wegovy remain in shortage, while there are no ...
The U.S. Food and Drug Administration removed Eli Lilly's (LLY.N), opens new tab blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on ...
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered ... The Food and Drug Administration said Wednesday that the shortage of Lilly’s Zepbound and Mounjaro ...
Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short ... “The tirzepatide injection shortage is resolved,” the US Food and Drug Administration ...
All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the United States after more than a year of being in shortage, according to the Food and Drug Administration’s ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...
The shortage of Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs is over ... “They are being cut off cold-turkey, their prescription no longer fillable,” he said in a statement.
News weighs on stocks of companies offering alternatives and some smaller ones developing their own drugs The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results